In conclusion, this study presented a promising efficacy of neoadjuvant PD-1 inhibitors plus chemotherapy for patients with resectable stage I–III NSCLC and tolerable toxicities. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.